NCT04215536View on ClinicalTrials.gov

Replication of the EMPAREG Diabetes Trial in Healthcare Claims

CompletedOBSERVATIONAL
Enrollment

103,752

Participants

Timeline

Start Date

July 8, 2019

Primary Completion Date

February 18, 2021

Study Completion Date

February 18, 2021

Conditions
Diabetes
Interventions
DRUG

Empagliflozin

Empagliflozin dispensing claim is exposure

DRUG

DPP-4 inhibitor

DPP4 inhibitor dispensing claim is reference

Trial Locations (1)

02120

Brigham & Women's Hospital, Boston

All Listed Sponsors
lead

Brigham and Women's Hospital

OTHER

NCT04215536 - Replication of the EMPAREG Diabetes Trial in Healthcare Claims | Biotech Hunter | Biotech Hunter